Mesoblast Limited vs Suncor Energy Inc. — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while Suncor Energy Inc. trades at $70.57 (market cap $80.03B). The key difference: Suncor Energy Inc. is far larger — about 44.2× Mesoblast Limited's market cap, and Suncor Energy Inc. pays a 2.49% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Suncor Energy Inc. for 57 Days on average.
| MESO | SU | |
|---|---|---|
Market Cap | $1.81B | $80.03B |
Volume | 240,620 | 2,907,827 |
Sector | Health | Energy |
52-Week High | $20.96 | $71.87 |
52-Week Low | $13.19 | $38.17 |
Typical Hold Time | 14 Days | 57 Days |
Enterprise Value | $1.89B | $86.58B |
Dividend Yield | — | 2.49% |
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Suncor Energy (SU) trades at $68.14, down 0.12% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with a P/E of 12.98, ROE of 19.25%, and consistent earnings beats in recent quarters. Recent news highlights strategic asset sales and leadership transitions, while analyst consensus remains strongly positive with 74% buy ratings. Cash flow trends show operational strength with $12.78B from operations in 2025.
SU presents a compelling value opportunity with attractive valuation metrics and robust shareholder returns through dividends and buybacks. Key risks include commodity price volatility and operational challenges from weather disruptions. The company's integrated model and international revenue diversification provide stability, though investors should monitor execution under new leadership and global energy market conditions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →